Follicular Lymphoma Clinical Trials

47 studies are recruiting for follicular lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

   This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lympho…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Westmead Hospital, Westmead, New South Wales

   Locations

   13 in total

   Run by

   Iksuda Therapeutics Ltd.

   See if you can join NCT05365659 on ClinicalTrials.gov

2. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   6 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

3. Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

   This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   C. Babis Andreadis

   See if you can join NCT04545762 on ClinicalTrials.gov

4. Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

   To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06108232 on ClinicalTrials.gov

5. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   City of Hope, Duarte, California

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

6. A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

   The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT wor…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07029217 on ClinicalTrials.gov

7. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

   Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope - Duarte Cancer Center ( Site 1301), Duarte, California

   Locations

   35 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07634471 on ClinicalTrials.gov

8. Clonal Evolution in Follicular Lymphoma

   Background: Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lym…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03190928 on ClinicalTrials.gov

9. CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

   This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclopho…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Marcela V. Maus, M.D.,Ph.D.

   See if you can join NCT06026319 on ClinicalTrials.gov

10. Emapalumab Prevention of CAR-T Cell Associated Toxicities

    This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Marcela V. Maus, M.D.,Ph.D.

    See if you can join NCT06550141 on ClinicalTrials.gov

11. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

    The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic - Scottsdale, Scottsdale, Arizona

    Locations

    46 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07226843 on ClinicalTrials.gov

12. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama At Birmingham Hospital, Birmingham, Alabama

    Locations

    114 in total

    Run by

    BeOne Medicines

    See if you can join NCT05006716 on ClinicalTrials.gov

13. Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

    The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06350318 on ClinicalTrials.gov

14. Epco, Zanu, Ritux for R/R FL or MZL

    The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research stud…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Reid Merryman, MD

    See if you can join NCT06563596 on ClinicalTrials.gov

15. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06784167 on ClinicalTrials.gov

16. Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio

    Locations

    2 in total

    Run by

    Paolo Caimi, MD

    See if you can join NCT07225439 on ClinicalTrials.gov

17. A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

    To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06043323 on ClinicalTrials.gov

18. Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

    BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

    Locations

    3 in total

    Run by

    Brown University

    See if you can join NCT04792502 on ClinicalTrials.gov

19. AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

    This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06340737 on ClinicalTrials.gov

20. HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

    The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohorts: follicular lymphoma (FL) and marginal zone lymphoma (MZ). Each cohort, FL and MZ, will be evalua…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Masonic Cancer Center, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT06792825 on ClinicalTrials.gov

21. A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

    The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Georgetown University (Data Collection Only), Washington D.C., District of Columbia

    Locations

    9 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05389293 on ClinicalTrials.gov

22. LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

    This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

    Stage

    Phase 1

    Ages

    18 to 81

    Site

    Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT05990465 on ClinicalTrials.gov

23. Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

    The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL). Study participants will undergo research blood collections of up to 60 mL as well as residual tissue collec…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Natera, Inc., Austin, Texas

    Run by

    Natera, Inc.

    See if you can join NCT07750886 on ClinicalTrials.gov

24. Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

    This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Emory University Hospital Midtown, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT03501576 on ClinicalTrials.gov

25. Allo HSCT Using RIC and PTCy for Hematological Diseases

    This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

    Stage

    Phase 2

    Ages

    Up to 75

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT05805605 on ClinicalTrials.gov